Detectable safety gestalt of rheumatoid arthritis treatments from pivotal clinical drug trials
Clicks: 1
ID: 318842
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #174 of 202 articles by views in Lara D. Veeken
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 202 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Objective To provide a meta-level comparison of standardized safety profiles (“gestalt”) of currently licensed biologic and targeted synthetic disease-modifying anti-rheumatic drugs (bDMARDs and tsDMARDs) in rheumatoid arthritis (RA) from pivotal clinical trials. Methods We systematically searched EMBASE, Medline and the Cochrane Library for randomized controlled RA drug approval trials of bDMARDs and tsDMARDs. The Medical Dictionary for Regulatory Activities (MedDRA) hierarchy system was applied to account for the heterogeneous safety reporting across trials, and random-effects meta-analyses of adverse events (AE) were performed at lower MedDRA levels as well as for major system organ classes. Serious adverse events (SAE) and AE of special interest (AESI) were studied descriptively. Forest plots and radar charts were used for visualization, to generate distinct safety profiles, referred to as “safety gestalt”, for each compound. Results Sixty-four randomized, placebo-controlled drug approval trials were considered, of which 25 studied tumour necrosis factor alpha inhibitors, 10 studied interleukin 6 receptor inhibitors, 5 studied rituximab, 7 studied abatacept, and 18 studied Janus kinase inhibitors. Meta-level comparisons of the total number of AE and SAE showed comparable overall safety and tolerability, while a more granular insight into distinct organ classes and AESI disentailed differences between compounds and drug classes. Conclusion Standardized safety reporting and profiling of bDMARDs and tsDMARDs from pivotal clinical drug trials provides an overview of safety outcomes of commonly used RA therapies, supports safety-oriented treatment selection in individual patients, and provides essential context for safety evaluation of novel therapies during periods before long-term safety data become available.
| Reference Key |
openalex_W7166027212
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Victoria Konzett, Andreas Kerschbaumer, Laurenz Willmann, Daniel Aletaha |
| Journal | Lara D. Veeken |
| Year | 2026 |
| DOI |
10.1093/rheumatology/keag263
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.